Eyebrow Reconstruction in Dormant Keratosis Pilaris Atrophicans

After four months of using minoxidil, finasteride, tretinoin, and microneedling, fine white fuzz appeared on bald patches. There is uncertainty if this fuzz will develop into full hair.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The conversation discusses using scalp micropigmentation (SMP) to disguise retrograde alopecia, with the user considering oral minoxidil and having experienced side effects from finasteride. Suggestions include trying different haircuts like skin fades and considering the potential downsides of SMP.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.